menu
    • menu

    Company profile for F. Hoffmann-La Roche

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    Contact Supplier

    Chirogate is a professional Prostaglandin manufacturer.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are known for pharmaceutical medicines since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to further drive personalised healt...
    We are known for pharmaceutical medicines since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to further drive personalised healthcare.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    F. Hoffmann-La RocheSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Konzern-Hauptsitz Grenzacherstrasse 124 CH-4070 Basel
    Telephone
    Telephone
    +41-61-688 1111
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.roche.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Not Confirmed

    envelop Contact Supplier

    CPhI North America

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    micAlchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

    Impressions: 284

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

    Radio Compass
    06 May 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaConnecting People, Mentalities & MarketsConnecting People, Mentalities & Markets

    Connecting People, Mentalities & Markets
    Connecting People, Mentalities & Markets

    reelConnecting People, Mentalities & Markets

    This PharmaReel highlights Transo-Pharm USA’s offerings of premium Phyto Cannabidiol (CBD) and Phyto Cannabigerol (CBG) isolates from its cGMP-certified facility inspected by the FDA and ANVISA. The company has an expanded reach across the US and EU.

    Impressions: 402

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions

    DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions

    The first quarter (Q1) of 2025 witnessed an impressive surge in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA), signaling a robust expansion in pharmaceutical development activities, the looming threat of tariffs notwithstanding.A total of 339 Type II DMFs were submitted during this period, as opposed to 235 submissions in Q1 2024, marking an exceptional increase of 44.26 percent. PharmaCompass’ data suggests that this is a record high for any first quarter.Overall, 440 DMFs were submitted across all categories (Types II, III, IV, and V) during Q1 2025, compared to 353 in the same period last year — representing a 24.65 percent increase.India and China continued to dominate the DMF landscape. India led with 162 submissions in Q1 2025, posting a remarkable 51.4 percent increase over 107 submissions recorded in Q1 2024. China followed with 135 submissions, representing a 33.66 percent increase over the 101 filings in Q1 2024.Taiwan sprung a surprise as a distant third. It made 12 DMF submissions in Q1 2025, as opposed to just one in Q1 2024. Western countries like the US, Spain, Germany, and Italy have maintained relatively stable or declining submission rates. Only the Netherlands showed significant growth with four DMF submissions in Q1 2025, up from zero in Q1 2024. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available)Indian giants MSN, Aurobindo, Cipla, Dr Reddy’s lead record-breaking DMF surgeIndia lived up to its “pharmacy of the world” reputation with the highest DMF submissions. In fact, seven of the top eight companies in the DMF tally were headquartered in India. MSN Group, emerged as the unequivocal leader with 23 submissions in Q1 2025, as against 15 in Q1 2024. Aurobindo Pharma increased its DMF activity from seven submissions in Q1 2024 to 12 in Q1 2025. Alivus Life Sciences, formerly known as Glenmark, made a dramatic leap with eight submissions in Q1 2025, quadrupling its previous year’s count of just two. Cipla more than doubled its DMF submissions — from three in Q1 2024 to eight in Q1 2025.Dr. Reddy’s Laboratories, one of India’s largest generic drugmakers, filed seven DMF submissions. The company’s Q1 2025 DMF portfolio includes high-value molecules like deucravacitinib, finerenone, enzalutamide, niraparib tosylate monohydrate, tucatinib, and tizanidine hydrochloride.Dr. Reddy’s has also indicated that they are open to manufacturing in the US. Meanwhile, Hetero Drugs filed seven submissions while Lee Pharma recorded six in Q1 2025.Chinese manufacturer Jiangsu East-Mab Biomedical Technology also established a significant presence with six DMFs. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Semaglutide, finerenone see most DMF submissions; first-time filings surge 64%Semaglutide and finerenone emerged as the most documented molecules in Q1 2025, each garnering nine DMF submissions. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized diabetes management and weight loss treatment, continues to attract significant manufacturer interest. Similarly, finerenone, a non-steroidal drug used in treating chronic kidney disease in type 2 diabetes patients, has garnered attention from manufacturers.Carfilzomib, used in multiple myeloma treatment, secured the third position with five DMF submissions. Deucravacitinib, a novel drug approved for moderate to severe plaque psoriasis, followed with four DMF submissions.There were several molecules with three DMF submissions each. Among them were tapinarof, a novel drug for psoriasis, and tirzepatide, a GLP-1/GIP receptor agonist that has shown remarkable efficacy in diabetes and weight management. During the quarter, 23 molecules received their inaugural DMF submissions. This number has risen by 64 percent since Q1 2024, when only 14 drugs saw their first DMF filings.In Q1 2025, these 23 first-time molecules collectively garnered 30 DMF submissions, with deucravacitinib emerging as the clear leader. Indian companies Dr. Reddy’s Laboratories and Cipla filed DMFs for this plaque psoriasis treatment as did Spain’s Curia and PMC Global.The Q1 2025 roster of first-time DMF filings include retatrutide (another GLP-1 receptor agonist), sotagliflozin, setmelanotide acetate, daridorexant, nusinersen, zavegepant, belzutifan, elacestrant dihydrochloride, selumetinib sulfate, sotorasib, atogepant, omadacycline tosylate, osilodrostat phosphate, ensifentrine, landiolol hydrochloride, maralixibat chloride, maribavir, methyl olivetolate, diazoxide choline, sparsentan, thinnertide, and vismodegib. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Our viewGiven Trump’s rhetoric around tariffs on imported drugs, the record-breaking DMF submissions in Q1 2025 sent out a strong message that the global pharmaceutical industry is willing to take on the complex geopolitical situation with resilience and strategic foresight.On a different note, the rise in DMF filings also indicate increased workload for the FDA staff, as also more inspections by the agency. It seems like more ‘laid off’ FDA employees will be asked to return to work in the coming days.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 570

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-surge-44-in-q1-2025-india-tops-list-with-51-rise-in-year-on-year-submissions

    #PharmaFlow by PHARMACOMPASS
    15 May 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    J&J, Pfizer and Roche face FDA questions over data applicability
    J&J, Pfizer and Roche face FDA questions over data applicability

    17 May 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/approval-bids-jj-pfizer-and-roche-fda-questions-data-applicability-ahead-adcomm

    FIERCE PHARMA
    17 May 2025
    Share Share
    Roche questions US investment plans after Trump executive order
    Roche questions US investment plans after Trump executive order

    15 May 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/roche-questions-us-investment-projects-wake-trumps-international-pricing-order

    FIERCE PHARMA
    15 May 2025
    Share Share
    Genentech honors hemophilia A caregivers in Hemlibra short film
    Genentech honors hemophilia A caregivers in Hemlibra short film

    14 May 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/marketing/genentech-pays-tribute-moms-children-hemophilia-hemlibra-short-film

    FIERCE PHARMA
    14 May 2025
    Share Share
    Roche boosts US presence with new $700M North Carolina facility
    Roche boosts US presence with new $700M North Carolina facility

    13 May 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/roche-invest-700-million-new-drug-manufacturing-facility-north-carolina-2025-05-12/

    REUTERS
    13 May 2025
    Share Share
    Roche invests $550 million to expand Indianapolis hub
    Roche invests $550 million to expand Indianapolis hub

    12 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/roche-announces-550-million-investment-to-expand-its-indianapolis-diagnostics-manufacturing-hub-302452305.html

    PR NEWSWIRE
    12 May 2025
    Share Share
    Roche puts up nearly $300M to expand manufacturing in China
    Roche puts up nearly $300M to expand manufacturing in China

    10 May 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/roche-pledges-nearly-300m-establish-new-vabysmo-production-plant-china

    FIERCE PHARMA
    10 May 2025
    Share Share

    Excipients

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Roche and get a quotation

    Roche is a supplier offers 101 products (APIs, Excipients or Intermediates).

    Find a price of Ceftriaxone bulk with CEP offered by Roche

    Find a price of Vitamin D3 bulk with JDMF offered by Roche

    Find a price of Bezafibrate bulk with CEP offered by Roche

    Find a price of Carvedilol bulk with CEP offered by Roche

    Find a price of Dextromethorphan Hydrobromide bulk with JDMF offered by Roche

    Find a price of Sulfadoxine bulk with CEP offered by Roche

    Find a price of Torsemide bulk with CEP offered by Roche

    Find a price of MSBA30K PEG REAGENT FOR MIRCERA (RO0503819) bulk with DMF offered by Roche

    Find a price of Acetazolamide bulk offered by Roche

    Find a price of Adenosine bulk offered by Roche

    Find a price of Altretamine bulk offered by Roche

    Find a price of Amitriptyline Hydrochloride bulk offered by Roche

    Find a price of Atropine Sulfate bulk offered by Roche

    Find a price of Beta Carotene bulk offered by Roche

    Find a price of Biotin bulk offered by Roche

    Find a price of Brompheniramine Maleate bulk offered by Roche

    Find a price of Butoconazole Nitrate bulk offered by Roche

    Find a price of Calcitriol bulk offered by Roche

    Find a price of Captopril bulk offered by Roche

    Find a price of Cetirizine Dihydrochloride bulk offered by Roche

    Find a price of Chenodeoxycholic Acid bulk offered by Roche

    Find a price of Chlordiazepoxide bulk offered by Roche

    Find a price of Chlorpheniramine Maleate bulk offered by Roche

    Find a price of Clonidine bulk offered by Roche

    Find a price of Debrisoquin bulk offered by Roche

    Find a price of Diphenhydramine Hydrochloride bulk offered by Roche

    Find a price of Disopyramide bulk offered by Roche

    Find a price of Doxylamine bulk offered by Roche

    Find a price of Doxylamine Succinate bulk offered by Roche

    Find a price of Etidronic Acid bulk offered by Roche

    Find a price of Etilevodopa bulk offered by Roche

    Find a price of Ferrous Fumarate bulk offered by Roche

    Find a price of Fluocytosine bulk offered by Roche

    Find a price of Flurbiprofen bulk offered by Roche

    Find a price of Glibenclamide bulk offered by Roche

    Find a price of Heparin Sodium bulk offered by Roche

    Find a price of Human Epidermal Growth Factor bulk offered by Roche

    Find a price of Hydrocortisone Acetate bulk offered by Roche

    Find a price of Ibuprofen bulk offered by Roche

    Find a price of Isotretinoin bulk offered by Roche

    Find a price of Ketoprofen bulk offered by Roche

    Find a price of Levorphanol Tartrate bulk offered by Roche

    Find a price of Meclizine Hydrochloride bulk offered by Roche

    Find a price of Meprobamate bulk offered by Roche

    Find a price of Methyl Testosterone bulk offered by Roche

    Find a price of Miconazole bulk offered by Roche

    Find a price of Neostigmine Methylsulfate bulk offered by Roche

    Find a price of Niacin bulk offered by Roche

    Find a price of Nufenoxole bulk offered by Roche

    Find a price of Phendimetrazine Tartrate bulk offered by Roche

    Find a price of Phenobarbital bulk offered by Roche

    Find a price of Phenylephrine Hydrochloride bulk offered by Roche

    Find a price of Phenylpropanolamine Hydrochloride bulk offered by Roche

    Find a price of Potassium Chloride bulk offered by Roche

    Find a price of Procarbazine Hydrochloride bulk offered by Roche

    Find a price of Pseudoephedrine Hydrochloride bulk offered by Roche

    Find a price of Pyridostigmine bulk offered by Roche

    Find a price of Pyridoxal Phosphate bulk offered by Roche

    Find a price of Riboflavin 5 Phosphate Sodium bulk offered by Roche

    Find a price of Sulfadimethoxine bulk offered by Roche

    Find a price of Tetrabenazine bulk offered by Roche

    Find a price of Theophylline bulk offered by Roche

    Find a price of Thiphenamil bulk offered by Roche

    Find a price of Thyrotropin-Releasing Hormone bulk offered by Roche

    Find a price of Ticlopidine bulk offered by Roche

    Find a price of Tretinoin bulk offered by Roche

    Find a price of Tromethamine API bulk offered by Roche

    Find a price of Ursodeoxycholic Acid bulk offered by Roche

    Find a price of Vitamin D3 bulk offered by Roche

    Find a price of Zalcitabine bulk offered by Roche

    Find a price of HYBEPHEN -LA CAPSULES bulk offered by Roche

    Find a price of FACILITIES CONTROL PERSONNEL bulk offered by Roche

    Find a price of B-AMINOPROPIONITRILE FUMARATE bulk offered by Roche

    Find a price of PROTAMINE HCL, RO 6-1588/1 bulk offered by Roche

    Find a price of FACILITIES UTILIZED IN DALRY, SCOTLAND bulk offered by Roche

    Find a price of RO 20 5933 bulk offered by Roche

    Find a price of NOLAMINE REPEAT ACTION TABLETS bulk offered by Roche

    Find a price of L bulk offered by Roche

    Find a price of PSEUDOEPHEDRINE HCL & CHLORPHENIRAMINE MALEATE S.R.C. bulk offered by Roche

    Find a price of INTERLEUKIN-2 (HUMAN, RECOMBINANT, E. COLI, HOFFMAN-LA ROCHE) bulk offered by Roche

    Find a price of FACILITIES AND OPERATING PROCEDURES IN SAO PAULO, BRAZIL bulk offered by Roche

    Find a price of MEDIGESIC PLUS CAPS bulk offered by Roche

    Find a price of THEOBID & THEOBID JR. S.R. CAPS 130MG & 260MG bulk offered by Roche

    Find a price of ACTIFED SUSTAINED RELEASE CAPSULES bulk offered by Roche

    Find a price of ANTIPRESS TAB bulk offered by Roche

    Find a price of MANUFACTURING FACILITIES AND CONTROLS bulk offered by Roche

    Find a price of ORTHO-NOVUM 1/5OE21 bulk offered by Roche

    Find a price of FLUOROLACTAM bulk offered by Roche

    Find a price of RO 5-9963 (DESMETHYLMISON IDAZOLE bulk offered by Roche

    Find a price of RO 3-1428 (5,8,LL,L4-EICOSATETRAYNOIC ACID) bulk offered by Roche

    Find a price of Entrectinib bulk offered by Roche

    Find a price of Erlotinib Hydrochloride bulk offered by Roche

    Find a price of Flumazenil bulk offered by Roche

    Find a price of Ganciclovir bulk offered by Roche

    Find a price of Granisetron bulk offered by Roche

    Find a price of Ibandronate Sodium bulk offered by Roche

    Find a price of Ketorolac Trometamol bulk offered by Roche

    Find a price of Oseltamivir Phosphate bulk offered by Roche

    Find a price of SPECIFICATIONS & DIRECTIONS FOR TESTING RAW MATERI bulk offered by Roche

    Find a price of ADITOPRIM bulk offered by Roche

    Find a price of CARBAZOLE ESTER bulk offered by Roche

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search